Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 9, 2012, Pages 1173-1180

  Bernstein, J A ^a   Shea, E P ^b   Koester, J ^b   Iarrobino, R ^b   Pullman, W E ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Dyax Corp   (United States)

Author keywords

C1 INH; ecallantide; hereditary angioedema; plasma kallikrein; relapse

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; EDEMA3; EDEMA4; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL SWELLING; ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; RELAPSE; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANGIOEDEMAS, HEREDITARY; CHILD; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KALLIKREINS; MALE; MIDDLE AGED; PEPTIDES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865000077     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2012.02864.x     Document Type: Article

References (25)

1. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139: 379-394.
2. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S30-S40.
3. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
4. Bernstein JA,. Update on angioedema: evaluation, diagnosis, and treatment. Allergy Asthma Proc 2011; 32: 408-412.
5. Bork K, Meng G, Staubach P, Hardt J,. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-274.
6. Zuraw BL,. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
7. Riedl M, Campion M, Horn PT, Pullman WE,. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105: 430-436.
8. Waytes AT, Rosen FS, Frank MM,. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-1634.
9. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M,. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-196.
10. Bork K, Staubach P, Eckardt AJ, Hardt J,. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619-627.
11. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 523-529.
12. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
13. Bernstein JA, Qazi M,. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010; 6: 29-39.
14. KALBITORÂ (ecallantide) [package insert]. In:, Corp D, editor. Cambridge, MA: Dyax Corp.; 2009.
15. Williams AH, Baird LG,. DX-88 and HAE: a developmental perspective. Transfus Apheres Sci 2003; 29: 255-258.
16. Banta EC, Craig TJ,. Overview of ecallantide in the treatment of hereditary angioedema types I and II. Therapy 2010; 7: 565-571.
17. Levy JH, O'Donnell PS,. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15: 1077-1090.
18. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE,. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011; 128: 153-159.
19. Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A,. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 2009; 18: 929-939.
20. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE,. Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011; 128: 153-159.e4.
21. Boccon-Gibod I, Bouillet L,. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-307.
22. Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-1611.
23. Banta E, Horn P, Craig TJ,. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc 2011; 32: 319-324.
24. Bork K, Meng G, Staubach P, Hardt J,. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45: 1774-1784.
25. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.